“…Current biochemical and structural studies are directed toward unraveling precise binding site and specific molecular interactions of these modulators with SF3B proteins. , A number of pharma and academic laboratories are working to bring derivatives of these compounds to clinical trials. , Furthermore, several spliceostatin derivatives have been designed for specific delivery of spliceostatin payloads using antibody–drug conjugates. ,, Since the isolation and discovery of the spliceostatin class of natural products, there has been immense interest in the total synthesis, structure–activity studies, exploration of novel structural derivatives, and development of spliceostatin natural product-based antisplicing drugs. Recently, Donaldson reported a short review on syntheses of spliceostatins and thailanstatins . The review focuses mainly on the synthesis, comparing route efficiency with respect to the number of steps, overall yield, and material cost of all synthetic methods through 2019 .…”